49. Systemic lupus erythematosus Clinical trials / Disease details
Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02429934 (ClinicalTrials.gov) | October 2015 | 24/4/2015 | Abatacept for SLE Arthritis (IM101-330) | Efficacy of Abatacept in Inflammatory Polyarthritis of Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus Arthritis | Biological: abatacept also known as Orencia also known as CTLA4-Ig;Drug: Placebo | University of California, Los Angeles | Bristol-Myers Squibb | Terminated | 18 Years | N/A | All | 28 | Phase 1/Phase 2 | United States |